(Albany, USA) DelveInsight’s “Uncomplicated Urinary Tract Infections (UTI) Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Uncomplicated Urinary Tract Infections market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Uncomplicated Urinary Tract Infections drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current Uncomplicated Urinary Tract Infections treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Request for sample report @ Uncomplicated Urinary Tract Infections Treatment Market
Uncomplicated Urinary Tract Infections (UTI) Market Key Facts
- The total uncomplicated UTIs market size across the 7MM reached USD 990 million in 2023, driven largely by the efficacy and usage of key antibiotics.
- According to DelveInsight’s estimates, the occurrence pool of uncomplicated urinary tract infections (UTIs) in 2023 reached approximately 36.35 million cases across the 7MM, with expectations for growth by 2034 at a significant CAGR.
- In 2023, the US held the largest market share for uncomplicated urinary tract infections (UTIs) within the 7MM, capturing approximately 63% of the total market.
- In the year 2021, the total occurrence-specific cases of uncomplicated urinary tract infection were 14,006 cases in EU-5. Italy recorded the highest number of occurrence-specific cases of uncomplicated urinary tract infections, followed by France and the United Kingdom.
- In Japan, the total occurrence-specific cases of uncomplicated urinary tract infections were 6,753 cases in the year 2021.
- On October 24, 2023, Iterum Therapeutics plc announced the completion of patient enrolment in its REASSURE clinical trial, comparing oral sulopenem to oral Augmentin in adult women with uncomplicated urinary tract infections (UTI). The trial, focusing on multi-drug resistant pathogens, finished ahead of schedule. Topline results are expected in early Q1 2024, with plans to resubmit the NDA to the FDA in Q2 2024. Corey Fishman, the CEO, highlighted the potential significance of bringing the first antibiotic for uUTIs in over 25 years and the first oral penem to the U.S. market.
- On November 3, 2022, GSK plc announced the premature cessation of enrollment in the pivotal phase III EAGLE-2 and EAGLE-3 trials for gepotidacin, an investigational treatment for uncomplicated UTI in females. This decision followed a recommendation by the Independent Data Monitoring Committee (IDMC) based on a pre-specified interim analysis of efficacy and safety data from over 3000 patients across the trials. Chris Corsico, SVP, Development, GSK, highlighted the urgent need for new antibiotics for uUTI, emphasizing the opportunity to engage with regulatory authorities to bring a new class of antibiotics to patients.
Request for sample report @ Uncomplicated Urinary Tract Infection Market Report
Uncomplicated Urinary Tract Infections (UTI) Overview
Urinary tract infection (UTI) is the most common bacterial infection caused by a range of pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. A urinary tract infection can develop in any part of the urinary tract, including the urethra, bladder, ureters, or kidneys. They are classified as either complicated or uncomplicated.
Uncomplicated urinary tract infections typically affect individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. Complicated urinary tract infection is associated with factors that compromise the urinary tract or host defense.
Uncomplicated Urinary Tract Infections Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Uncomplicated Urinary Tract Infections pipeline therapies. It also thoroughly assesses the Uncomplicated Urinary Tract Infections market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Uncomplicated Urinary Tract Infections drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Request for Uncomplicated Urinary Tract Infections epidemiology trends and population @ Uncomplicated Urinary Tract Infections Prevalence
Uncomplicated Urinary Tract Infections Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Uncomplicated Urinary Tract Infections epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted Uncomplicated Urinary Tract Infections epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Uncomplicated Urinary Tract Infections Epidemiology, Segmented as –
- Total Occurrence-specific cases of Uncomplicated Urinary Tract Infection
- Total Diagnosed Cases of Uncomplicated Urinary Tract Infection
- Total Age-specific Cases of Uncomplicated Urinary Tract Infection
- Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection
- Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection
Uncomplicated Urinary Tract Infections Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Uncomplicated Urinary Tract Infections market or expected to be launched during the study period. The analysis covers the Uncomplicated Urinary Tract Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Uncomplicated Urinary Tract Infections drugs based on their sale and market share.
The report also covers the Uncomplicated Urinary Tract Infections pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Uncomplicated Urinary Tract Infections companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Uncomplicated Urinary Tract Infections Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market
Uncomplicated Urinary Tract Infections Companies Actively Working in the Therapeutics Market Include
- GlaxoSmithKline
- Iterum Therapeutics
- Inmunotek
- Janssen Pharmaceuticals
- Fimbrion Therapeutics
And Many More
Emerging and Marketed Uncomplicated Urinary Tract Infections Therapies Covered in the Report Include:
- GSK2140944/Gepotidacin (GlaxoSmithKline)
- Sulopenem Etzadroxil – Probenecid (Iterum Therapeutics)
- Uromune/MV140 (Inmunotek)
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @ Uncomplicated Urinary Tract Infections Clinical Trials
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Uncomplicated Urinary Tract Infections Competitive Intelligence Analysis
4. Uncomplicated Urinary Tract Infections Market Overview at a Glance
5. Uncomplicated Urinary Tract Infections Disease Background and Overview
6. Uncomplicated Urinary Tract Infections Patient Journey
7. Uncomplicated Urinary Tract Infections Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Uncomplicated Urinary Tract Infections Treatment Algorithm, Current Treatment, and Medical Practices
9. Uncomplicated Urinary Tract Infections Unmet Needs
10. Key Endpoints of Uncomplicated Urinary Tract Infections Treatment
11. Uncomplicated Urinary Tract Infections Marketed Therapies
12. Uncomplicated Urinary Tract Infections Emerging Drugs and Latest Therapeutic Advances
13. Uncomplicated Urinary Tract Infections Seven Major Market Analysis
14. Attribute Analysis
15. Uncomplicated Urinary Tract Infections Market Outlook (In US, EU5, and Japan)
16. Uncomplicated Urinary Tract Infections Companies Active in the Market
17. Uncomplicated Urinary Tract Infections Access and Reimbursement Overview
18. KOL Views on the Uncomplicated Urinary Tract Infections Market
19. Uncomplicated Urinary Tract Infections Market Drivers
20. Uncomplicated Urinary Tract Infections Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/market-assessment-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Uncomplicated Urinary Tract Infections (UTI) Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight